CJC-1295 with DAC
Symbol Cd · MW 3647 Da
DAC-conjugated, long-acting GHRH analog elevating GH and IGF-1 baselines.
- Discovered
- 2006
- Half-life
- 7 days
- Approval
- Not FDA-approved
Quick facts
- Category
- Hormone
- Route
- Injectable
- Molecular weight
- 3647 Da
- Half-life
- 7 days
- Discovered
- 2006
- Approval status
- Not FDA-approved
Reported effects
- Sustained GH support
- Recovery
- Lean mass
Overview
CJC-1295 with DAC is a longer-acting version of CJC-1295 designed to extend growth hormone-releasing activity in the body. DAC stands for Drug Affinity Complex, which allows the peptide to bind to albumin and remain active for a longer period. This extended half-life makes CJC-1295 with DAC a more sustained growth hormone secretagogue compared with shorter-acting options. It is commonly associated with hormone optimization, recovery support, lean body composition, and sleep quality. Its purpose is to provide longer-lasting stimulation of the body's natural growth hormone release.
Evidence context
CJC-1295 with DAC evidence summary
Human clinical evidence
CJC-1295 with DAC has an approval context listed in the Peptidic database. Approved use still depends on the specific indication, formulation, labeling, and clinician guidance.
Animal, preclinical, or formulation evidence
CJC-1295 with DAC may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for CJC-1295 with DAC as Not FDA-approved. The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- No established approved dosage; commonly referenced range is 1–2 mg weekly
- Typical Frequency
- Once or twice weekly
Dosing depends on the approved indication, formulation, titration schedule, and clinician guidance. This page is educational and not a substitute for medical advice.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on CJC-1295 with DAC.
Internal links
Related peptides
Frequently asked questions
What category is CJC-1295 with DAC in?
CJC-1295 with DAC is listed in the Hormone category on Peptidic.
What route is CJC-1295 with DAC associated with?
CJC-1295 with DAC is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is CJC-1295 with DAC approved?
Peptidic lists the approval status for CJC-1295 with DAC as: Not FDA-approved. Approval details can vary by indication and jurisdiction.
Interested in CJC-1295 with DAC?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01